Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017)

Margaret L. Musser1,2*, Kathryn L. Taikowski1,3, Chad M. Johannes2 and Philip J. Bergman4

Abstract

Background: Effective treatment options for inoperable, metastatic, or recurrent canine pheochromocytomas are lacking. In humans, specific germline mutations exist that drive the development of pheochromocytomas. Pharmaceutical blockade of these abnormalities with small molecule inhibitors are an effective treatment strategy. Similar mutations may exist in the dog, and thus, treatment with similar small molecule inhibitors may provide a survival advantage. The purpose of this study was to assess the role of toceranib phosphate in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas.

Results: Retrospectively, medical records of dogs that had a diagnosis or suspect diagnosis of a pheochromocytoma were reviewed for information regarding response to toceranib phosphate and overall outcome. Five dogs were identified that fit the inclusion criteria. All five experienced clinical benefit (1 partial response, 4 stable disease). Progression-free interval (PFI) for the dog with the partial response was 61 weeks. PFI for the two dogs with stable measurable disease were 36 weeks and 28 weeks. PFI in the two dogs with stable metastatic disease were at least 11 weeks and 18 weeks.

Conclusions: Based on this limited series of dogs, the results suggest that toceranib may have biological activity in dogs with primary and metastatic pheochromocytomas. Larger studies are needed to define the use and response to toceranib in dogs with gross, microscopic, and metastatic pheochromocytoma.

Keywords: Pheochromocytoma, Toceranib, Canine, Metastasis, Recurrent

Background

Pheochromocytomas (PCs) are tumors comprised of neoplastic chromaffin cells of the adrenal medulla. Pheochromocytomas overproduce catecholamines, specifically epinephrine and norepinephrine, in an episodic manner, leading to intermittent clinical signs, including weakness, collapse, hypertension, panting, polyuria and polydipsia, and decreased appetite [1, 2]. Pheochromocytomas are uncommon in the dog, but must be considered malignant as severe consequences including invasion into the caudal vena cava, retroperitoneal hemorrhage, and metastatic spread can occur [2, 3].

Definitive treatment of a PC requires adrenalectomy [2]. However, anesthesia and surgical removal of an adrenal tumor is a high-risk procedure, carrying an overall 51% postoperative complication rate, which increases to 60% in dogs with PC [4]. These complications can include significant blood pressure variations, tachyarrhythmias, intraoperative hemorrhage, and intraoperative death [3, 4]. Vascular invasion into the caudal vena cava, reported in up to 82% of cases, [4, 5] complicates the surgical approach, but the impact on survival in these cases is unclear [4–6].
A median survival time of 53 weeks has been reported in dogs following surgical removal of a PC [7], with some living for 2–3 years [8, 9]. However, some PCs are not amenable to surgical removal or surgery is contraindicated due to the presence of widespread metastatic disease [6]. The benefit of medical treatment in these cases is unknown.

Pheochromocytomas affect 2 to 8 per million people per year [10, 11] and are biologically similar to those that affect dogs [1]. Standard of care is surgical removal, which often results in a normal lifespan for those individuals with local disease. However, 10–30% will develop distant metastatic disease, and in the 6.5 to 16.5% of patients that develop recurrence after surgical removal [12–14], 50% develop distant metastasis [14]. In the case of any distant metastasis, only 40–60% of patients survive an additional 5 years [1, 15]. These advanced-stage malignant PCs are resistant to chemotherapy and radiation therapy, and the side effects of treatment often outweigh the benefits [16].

In humans, hereditary germline mutations, and abnormally regulated angiogenesis and oxygen metabolism pathways, drive the pathogenesis of many metastatic PCs [17]. Therefore, recent PC research and clinical trials have focused on drugs that target these specific abnormalities. Sunitinib malate is a small molecule inhibitor that targets multiple tyrosine kinase receptors, including c-KIT, FLT3 and RET, and those that help to drive angiogenesis including vascular endothelial growth factor receptors (VEGFR) 1 and 2, and platelet-derived growth factor receptor-β (PDGFRβ) [12, 17, 18]. Recent research suggests that use of sunitinib in human patients with advanced PCs will result in tumor size reduction, disease stabilization, and improvement of hypertension [16, 17, 19, 20].

Toceranib phosphate is a tyrosine kinase inhibitor (TKI) available in veterinary medicine that is molecularly similar to sunitinib, and blocks the same key receptors associated with angiogenesis: VEGFR and PDGFR [21, 22]. Thus, it may be a good treatment option for canine patients suffering from advanced PCs that are biologically similar to human PCs, or in those patients where surgical removal is not a viable treatment option. This study aimed to determine if a response to toceranib is present in dogs with advanced inoperable, recurrent, or metastatic PCs. Based on the human literature, we hypothesized that dogs with a measurable PC or metastatic disease would have a biological response to treatment with toceranib.

**Methods**

Medical records of dogs diagnosed with a PC and treated with toceranib were collected and reviewed via solicitation through the American College of Veterinary Internal Medicine Oncology Listserv, an e-mail based forum for oncology diplomats. Only dogs with complete records regarding signalment, history, initial complaint, physical examination findings, abdominal and thoracic imaging, treatment with toceranib for at least 10 weeks, and with adequate follow-up including records of side effects, were included in the study. The diagnosis of a PC was based on histopathology of the surgically removed tumor, or suspicion of a PC based on elevated plasma or urine metanephrine or normetanephrine levels as previously described [3, 23–27].

Data collected included breed, weight, clinical signs at diagnosis and duration of clinical signs, findings of thoracic and abdominal imaging, histopathology results, blood pressure, results of fundic examinations, urine metanephrine/normetanephrine levels if available, evidence of cardiac arrhythmias, therapy prior to the start of toceranib, reason for toceranib use (inoperable measurable disease, microscopic disease, treatment of recurrent disease, metastatic disease, or maintenance after completion of other therapy), toceranib dose and dose schedule, duration of toceranib treatment, best response to treatment using previously defined criteria [28], side effects induced by toceranib using the veterinary cooperative oncology group-defined criteria [29], concurrent chemotherapy and supportive medications, concurrent diseases, and patient outcome.

Progression-free interval (PFI) was calculated for all dogs and defined as the time from the day of first toceranib treatment to the time of disease progression (defined as either local regrowth, local progression, and/or metastasis), to the time of toceranib discontinuation due to adverse effects, or to the time of data submission. For dogs with measurable disease, as in previous publications describing the use of toceranib in dogs, clinical benefit (CB) was determined by best response to therapy and was defined as a complete response (CR) or partial response (PR) of any duration, or stable disease (SD) of at least ten weeks in duration [30].

Response to therapy was evaluated via serial abdominal ultrasounds, thoracic radiographs, and in one case urine catecholamine measurements. Animals experiencing SD less than 10 weeks in duration or progressive disease (PD) as their best response to toceranib were not classified as achieving CB.

**Results**

Data for 6 dogs from 5 different sites were received. Five dogs were identified that fit the inclusion criteria (Table 1).

The sixth dog did not have adequate evidence of a PC diagnosis, and so was excluded from analysis. There were four spayed females and one castrated male. Breeds included one of each: Shih Tzu, Australian Terrier, Pomeranian, Dachshund, and Pit Bull. Mean weight was 12.1 kg (range 2.6–29 kg) with a mean age of 11.5 years (range 9.5–14 years). Clinical signs at diagnosis were varied, but included prolonged gastrointestinal signs (vomiting,
diabetes, decreased appetite, and weight loss) in three
dogs, and exercise intolerance, heavy panting, and poly-
uria/polydipsia in two dogs. One dog was non-clinical
and the PC was an incidental finding during work-up of
a concurrent disease. Excluding this dog, clinical signs
for the other four dogs were present for a mean of
22 weeks (range 1–52 weeks).

Physical examinations were unremarkable in all dogs.
No cardiac arrhythmias were noted in any dogs at any
time. A fundic examination was performed in four dogs,
which was normal in all patients evaluated.

Abdominal radiographs were taken in one dog, which
revealed mild hepatomegaly and a small liver mass. An
abdominal ultrasound was completed in all dogs; all
were diagnosed with a right-sided unilateral adrenal mass.
Three of the dogs had evidence of caudal vena caval
invasion. One additional dog developed a recurrent adrenal
mass with invasion of the caudal vena cava one year after
initial PC diagnosis and surgical treatment. Additional
ultrasonographic findings included mesenteric lymphad-
nopathy concerning for metastatic disease (n = 1), an inci-
dental splenic mass (n = 1), an incidental caudal abdominal
mass (n = 1), mild hepatomegaly consistent with vacuolar
hepatopathy (n = 3), renal cortical hyperechogenicity con-
sistent with degenerative renal changes (n = 3), mild pan-
creatic enlargement and hyperechogenicity consistent with
chronic pancreatitis (n = 1), scant peritoneal effusion (n =
1), mild urinary bladder wall thickening (n = 1), and one
patient with multiple ventral caudal abdominal subcutane-
ous nodules suspected to be metastasis from a previously
diagnosed mammary carcinoma (given location and the
reported subcutaneous metastatic rate of 30% for canine
mammary carcinomas [31]; diagnostic sampling was
not pursued).

An abdominal CT scan was completed in two dogs for
further evaluation of the adrenal mass. This confirmed
the presence of the suspected adrenal mass in both dogs.
In addition, in one patient invasion of the adrenal mass
into the phrenicoabdominal vein and right liver was
identified, which was not clear on the abdominal ultra-
sound completed prior to the CT scan.

Two dogs were diagnosed with adrenal PC based on
elevated urine catecholamine levels evaluated through

| Patient | Breed       | Treatment of Measurable Disease or Metastatic Disease | Response | PFI (weeks) | Reason for Toceranib Discontinuation | Alive? |
|---------|-------------|-------------------------------------------------------|----------|-------------|-------------------------------------|--------|
| 1       | Shih Tzu    | Measurable                                            | SD       | 36          | Diarrhea                            | Y      |
| 2       | Aus. Terrier| Microscopic/Metastatic                                 | SD       | 18          | Ongoing                             | Y      |
| 3       | Pomeranian  | Measurable                                            | SD       | 28          | Ongoing                             | Y      |
| 4       | Dachshund   | Measurable                                            | PR       | 61          | Ongoing                             | Y      |
| 5       | Pit Bull    | Metastatic                                            | SD       | 11          | Lameness                            | N      |

PFI: Progression free interval

Marshfield Labs. One dog had an elevated normetanephr-
ine/creatinine ratio (2268 μg/g creatinine; reference interval [RI] 28–380 μg/g creatinine). The other had an elevated norepinephrine/creatinine ratio (0.152 μg/mg creatinine; RI 0.001–0.037 μg/mg creatinine) and an elevated dopamine/creatinine ratio (0.1 μg/mg creatinine; RI 0.00–0.031 μg/mg creatinine). The remaining three dogs did not have urine or plasma catecholamine levels evaluated.

Full staging (thoracic and abdominal imaging) was
completed for all dogs, which revealed that at diagnosis
three dogs had evidence of suspect metastatic disease.
One dog had pulmonary metastatic disease based on CT
(thoracic radiographs were not completed). The remaining
four dogs were free of pulmonary metastatic disease based
on thoracic radiographs. One dog had evidence of several
enlarged mesenteric lymph nodes on ultrasound concern-
ning for early metastatic disease (as mentioned above). CT
scan identified a suspect bony lesion in L1 of one addi-
tional dog which was concerning for metastatic disease.
No dogs had evidence of multiple endocrine neoplasia
syndromes type 1 or 2.

Three dogs underwent surgical removal of their adrenal
tumors and had a histologic diagnosis of PC. Additional
surgical findings included a caudal abdominal lipoma, a
splenic hematoma, and chronic hepatopathy (abnormal-
ities noted previously on ultrasound, as described above).
One dog that was treated surgically had evidence of caudal
vena cava invasion at surgery, but not during the planning
abdominal ultrasound. A CT scan was not completed in
this dog. The three dogs that received surgical treatment
also had blood pressure readings taken prior to and
after surgical removal of the pheochromocytoma. Mean
blood pressure prior to surgery was 135 mmHg (range
72–204 mmHg). Mean blood pressure after surgery was
113 mmHg (range 80–151 mmHg).

In the three dogs that had surgical removal of their
PC, toceranib therapy was started at the time of recurrent,
inoperable disease in one dog, for adjuvant treatment of
incomplete surgical margins and the development of pul-
monary metastatic disease in the second, and for treat-
ment of pulmonary metastatic disease in the third. In the
remaining two dogs, toceranib was given to treat inoper-
able measurable disease.
All dogs received toceranib at a starting target dose of 2.75 mg/kg orally, rounded up to the nearest available tablet size, every other day \((n = 1)\) or Monday, Wednesday, and Friday \((n = 4)\). At the time of data submission, three dogs were still receiving toceranib; two had treatment discontinued due to adverse side effects (one due to grade 2–3 lameness; one due to grade 2 diarrhea, grade 2 anorexia, grade 2 lethargy, and grade 3 liver enzyme elevations). Two of the three still receiving treatment had been on continuous toceranib for seven and eight months. The third had been on toceranib for a total of 17 months, including a one-month treatment break following the development of an elevated urine protein/creatinine ratio, which resolved after the treatment break. The two patients no longer on toceranib had been treated for a total of six and nine months. One patient was treated concurrently with metronomic cyclophosphamide (dog 5). Additional supportive medications included enalapril \((n = 3)\), metronidazole \((n = 2)\), maropitant \((n = 1)\), famotidine \((n = 1)\), s-adenosylmethionine and silybin A + B \((n = 1)\), amiodipine \((n = 1)\), carprofen \((n = 1)\), gabapentin \((n = 1)\), tramadol \((n = 1)\), and omeprazole \((n = 1)\).

Four dogs had a normal blood pressure prior to starting toceranib (one dog was not evaluated). During toceranib treatment, two dogs developed hypertension (defined as a mean systolic blood pressure of > 160 mmHg as previously described [32]) greater than 220 mmHg. Enalapril was started in both dogs which resulted in the normalization of the blood pressure. In both dogs enalapril was continued for the duration of toceranib therapy.

Three dogs required a treatment break, discontinuation, or decreased dose due to adverse side effects. One dog developed grade 2 diarrhea, grade 2 anorexia, grade 2 lethargy, and grade 3 liver enzyme elevations that progressed while on toceranib. Several drug holidays were pursued, which resulted in temporary control of adverse effects, but even at a lower dose the gastrointestinal signs returned and toceranib was ultimately discontinued after nine months of treatment. One dog developed grade 1 diarrhea and grade 3 proteinuria. Enalapril was started for the proteinuria and a one-month break was given. This resolved the proteinuria and toceranib was restarted at a lower dose \((1.9 \text{ mg/kg PO Monday, Wednesday, Friday})\). One dog experienced grade 2–3 lameness which resulted in toceranib discontinuation (Table 1).

Clinical benefit (CR, PR, SD) was noted for all five dogs (Table 1). Four of the dogs treated with toceranib had SD. For these four dogs, PFI was determined to be at least 11, 18, 28, and 36 weeks. In one of these dogs, response was evaluated via an additional urine normetanephrine/creatinine ratio which showed normalization of the ratio following the start of toceranib treatment (levels decreased from 2268 μg/g creatinine to 326 μg/g creatinine; RI 28–380 μg/g creatinine). The fifth dog had a PR with a PFI of 61 weeks that as of data submission is on-going.

At the time of data submission, four dogs were still alive. One dog (dog 5) had been humanely euthanized due to progressive metastatic pulmonary disease 23 months after surgery to remove the primary PC, and 11 months after starting toceranib therapy for metastatic disease. The dog was on a total of six months of toceranib which was discontinued five months prior to euthanasia due to lameness and negative impact on quality of life.

**Discussion**

The aim of this retrospective study was to evaluate the biologic response of dogs with inoperable, metastatic, or recurrent PCs to standard toceranib treatment. Beyond surgical removal, which is the treatment of choice, information about adjuvant therapy is lacking. The best treatment practices for inoperable, recurrent, or metastatic tumors is also unknown. Based on this limited case series, it appears that toceranib may have biological activity in dogs with microscopic and macroscopic PCs (primary or metastatic disease), and that toceranib might be a reasonable treatment option for owners who are hesitant to pursue surgery, for tumors that are not amenable to surgical removal, and for dogs with distant metastatic disease.

Pheochromocytomas in humans and dogs are clinically similar. Optimal treatment centers on surgical removal, with limited treatment options for inoperable tumors, those that are metastatic, and those that are recurrent. In humans, intensive chemotherapy, radiation therapy, and radiopharmaceutical agents \((^{131}I\)-metaiodobenzylguanidine\) result in palliation of symptoms, but do not have an impact on survival [16]. Tyrosine kinase inhibitors that target c-KIT, FLT3, RET, VEGFR 1 and 2, or PDGFRβ appear to have the best biological response, reported to be around 60% [16, 17, 19, 20].

In humans, hereditary germline mutations and mutations in the von Hippel-Lindau (VHL) gene lead to the development of multiple neuroendocrine tumors including PCs [17]. An abnormally functioning VHL gene allows the activation of hypoxia-inducible transcription factors (HIF) which in turn promotes cell growth, angiogenesis, cell survival, and activation of VEGF and PDGF [33]. Similarly, mutations in succinate dehydrogenase (SDH) subunits B and D lead to the activation of HIF and the development of aggressive PCs [1]. Blockade of these mutations with small molecule inhibitors such as sunitinib via the VEGFR cell signaling pathway have led to improved quality of life, tumor size reduction, and control of PC-induced clinical signs such as hypertension [17].

One study has evaluated canine PCs, and the related paraganglioma, for SDH mutations. In that study 50% of PCs (3/6) had germline mutations in SDH, indicating that the disease may have some genetic similarities to
humans [34]. Canine VHL mutations have been evaluated in canine renal carcinoma [35], but not yet in PCs, to the authors’ knowledge. However, due to the evidence of SDH mutations and similar pathogenesis, it seems reasonable to conclude that human and canine PCs may be similar in their development, and thus treatment with similar TKIs blocking the VEGFR pathway may offer a therapeutic advantage for our canine patients.

Despite these similarities, the reported treatment of PCs in dogs has been largely limited to surgical removal. One case report describes the use of the radiopharmaceutical 131I-metaiodobenzylguanidine for an inoperable PC in a Yorkshire terrier [36]. 131I-metaiodobenzylguanidine is an alkyl-guanidine derivative with a molecular structure similar to norepinephrine. Selective uptake by a PC will occur after intravenous administration. The dog experienced stable disease for one and a half months after the first injection, but five months later developed progressive disease. A second injection was administered but the patient died three weeks later, likely due to compression-induced bowel ischemia [32]. To the authors’ knowledge, there are no reported studies of chemotherapy or toceranib for the treatment of canine PCs.

Toceranib phosphate is an oral TKI approved for the use in dogs with Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement. However, it appears to have efficacy against multiple tumors types, including various neuroendocrine tumors [30]. It is known to block multiple receptors including VEGFR and PDGFR [21] that stimulate angiogenesis, a known driver of human PCs.

Three dogs developed grade 1 or 2 clinical toxicities, which is in keeping with the previously reported toxicity rate for toceranib of 77.6% [30]. In addition, the toxicities observed, such as diarrhea, decreased appetite, lameness/muscle weakness, proteinuria, and hypertension, were those previously associated with toceranib [30, 32]. Neutropenia was not reported in this group of dogs. Two dogs had effects that were severe enough to warrant discontinuation of toceranib, and an additional patient required a significant dose reduction due to grade 3 proteinuria. In a recent study evaluating the use of toceranib in solid tumors, 20% of patients required a drug holiday or dose reduction, although this reduction did not appear to affect efficacy [37]. The number of dogs in this study that required discontinuation of treatment was much higher, but that is likely due to low patient numbers and lack of statistical power.

Two dogs developed hypertension, one of which was the same dog that developed grade 3 proteinuria. Hypertension is a known side effect of toceranib and has previously been reported to occur in 37% of treated dogs [32]. Hypertension is also a well-known side effect in humans treated with sunitinib. In a systematic review of the side effects associated with TKIs for the treatment of gastrointestinal stromal tumors, which inherently should not cause hypertension like PCs, 36% of human patients developed hypertension while on sunitinib [38]. In addition, in a study of humans with PC and paragangliomas treated with sunitinib, 82% had hypertension at presentation, and 35% had exacerbation of their hypertension while on sunitinib [17]. The underlying pathogenesis of TKI-induced hypertension is unknown. Prevailing theories include: (1) VEGF blockade, which prevents nitric oxide synthetase production of nitric oxide, allowing endothelin driven vasoconstriction; (2) decreased VEGF which may remodel capillaries and lead to endothelial dysfunction; or perhaps (3) TKIs may induce tumor cell apoptosis, leading to release of stored catecholamines and thus hypertension [39]. Recently, it has been determined that the development of hypertension while on a TKI is a biomarker of efficacy in some human patients treated with sunitinib [40]. In the current study, the two dogs that developed hypertension after starting treatment with toceranib both had a prolonged PFI (28 weeks and 61 weeks, respectively), and include the one dog that had a PR. One could make the argument that the development of hypertension may infer a more robust and durable response to toceranib.

There are many limitations to the current study due to its retrospective nature and small patient numbers. Histopathologic confirmation of a PC diagnosis was not obtained in all dogs. However, this is often the case in practice as a presurgical presumptive diagnosis of PC is frequently based on clinical signs and abdominal imaging alone [1, 2, 8]. The addition of urine normetanephrine/creatinine ratio measurement may aid in the diagnosis of pheochromocytoma, allowing for appropriate targeted therapy. However, sensitive and specific reference ranges have not been established to confirm the diagnosis of a PC in all clinical situations [23–27]. In addition, this diagnostic is not readily available at most laboratories (available, to the authors’ knowledge, through Marshfield Labs, ARUP Labs, and some local human hospitals). Similarly, metastatic disease, although suspected in several dogs, was not confirmed at the time of development or on necropsy. In addition, the natural course of this cancer in these dogs prior to diagnosis and the impact of toceranib on that natural progression, is unknown.

One dog received metronomic cyclophosphamide in addition to the toceranib. Although cyclophosphamide is used to treat humans with PC in a combination protocol with vincristine and dacarbazine, use as a single agent has not been reported [41]. In addition, low-dose metronomic cyclophosphamide (used in the dog reported herein), has not been evaluated for efficacy in human or canine PC. The impact of the addition of cyclophosphamide on this dog’s outcome is unknown, but may have positively contributed to the stable disease observed (dog 5). Therefore, given these caveats, it is impossible
to definitively conclude that toceranib has clinical benefit for canine PCs.

Conclusions
Despite the aforementioned limitations, this study suggests that toceranib may offer clinical benefit to dogs with PCs. Additional studies investigating the presence of germline mutations similar to those identified in humans could help to support this conclusion. Furthermore, prospective studies are needed to better elucidate the potential role of toceranib in the treatment of both macroscopic and microscopic PCs.

Abbreviations
CB: Clinical benefit; CR: Complete response; HIF: Hypoxia-inducible transcription factors; PCs: Pheochromocytomas; PD: Progressive disease; PDGFRβ: Platelet-derived growth factor receptor-β; PFI: Progression-free interval; PR: Partial response; RI: Reference interval; SD: Stable disease; SDH: Succinate dehydrogenase; TKI: Tyrosine kinase inhibitor; VEGFRs: Vascular endothelial growth factor receptors; VHL: von Hippel-Lindau gene

Acknowledgements
The authors would like to thank doctors Antony Moore, Karen Oberthaler, Sharon Shor, and Carrissa Wood, for contributing dogs to this study.

Funding
No third-party support or funding was received in connection with this study.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MLM, KLT, and PJB designed this retrospective study. MLM and KLT supervised case information collection and data analysis. MLM and KLT wrote the manuscript. MLM, KLT, CMI, and PJB assisted in writing and final editing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable – retrospective records review.

Consent for publication
Not applicable

Competing interests
CMI is a former employee of Pfizer Animal Health and has served as a member of the Zoetis Inc. (formerly Pfizer Animal Health) Oncology Advisory Board and occasionally received honoraria for these activities. PJB is a Palladia Advisory Board member and has ongoing studies sponsored by Zoetis. The remaining authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1VCA Veterinary Referral and Emergency Center, Norwalk, CT, USA. 2Present address: Iowa State University College of Veterinary Medicine, Ames, IA, USA. 3Present address: Ohio State University College of Veterinary Medicine, Columbus, OH, USA. 4VCA Clinical Studies, Los Angeles, CA, USA.
25. Quante S, Boretti FS, Kook PH, et al. Urinary catecholamine and metanephrine to creatinine ratios in dogs with hyperadrenocorticism or pheochromocytoma, and in healthy dogs. J Vet Intern Med. 2010;24(5):1093–7.
26. Green BA, Frank EL. Comparison of plasma free metanephrines between healthy dogs and 3 dogs with pheochromocytoma. Vet Clin Pathol. 2013;42(4):499–503.
27. Salesov E, Boretti FS, Sieber-Ruckstuhl NS, et al. Urinary and plasma catecholamines and metanephrines in dogs with pheochromocytoma, hypercortisolism, nonadrenal disease and in healthy dogs. J Vet Intern Med. 2015;29(2):597–602.
28. Nguyen SM, Thamm DH, Vail DM, et al. Response evaluation criteria for solid tumors in dogs (v1.0); a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2015;13(3):176–83.
29. Veterinary cooperative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417–46.
30. London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (palladia®) in solid tumours. Vet Comp Oncol. 2012;10(3):194–205.
31. Moulton JE, Taylor DON, Doran CR, et al. Canine mammary tumors. Vet Path. 1971;7:289–320.
32. Tjostheim SS, Stepien RL, Markovic LE, et al. Effects of toceranib phosphate in systolic blood pressure and proteinuria in dogs. J Vet Intern Med. 2016;30(4):951–7.
33. Dahia PLM. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14(2):108–19.
34. Holt DE, Henthorn P, Howell VM, et al. Succinate dehydrogenase subunit D and succinate dehydrogenase subunit B mutation analysis in canine pheochromocytoma and paraganglioma. J Comp Pathol. 2014;151(1):25–34.
35. Pressler BM, Williams LE, Ramos-Vara JA, et al. Sequencing of the von Hippel-Lindau gene in canine renal carcinoma. J Vet Intern Med. 2009;23(3):592–7.
36. Bommarito DA, Lattimer JC, Selting KA, et al. Treatment of a malignant pheochromocytoma in a dog using 131I metaiodobenzylguanidine. J Am Anim Hosp Assoc. 2011;47(6):e188–94.
37. Bernabe LF, Portela R, Nguyen S, et al. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res. 2013;9:190.
38. Sodergren SC, White A, Efficace F, et al. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumors of behalf of the EORTC quality of life group. Crit Rec Oncol Hematol. 2014;91(3):35–46.
39. Aparicio-Gallego G, Gonzo-Afonso FJ, León-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitinib. Anti-Cancer Drugs. 2011;22(1):1–8.
40. George S, Reichardt P, Lechner T, et al. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012;23(12):3180–7.
41. Scholz T, Eisenhofer G, Pacak K, et al. Clinical review: current treatment of malignant phaeochromocytoma. J Clin Endocrinol Metab. 2007;92(4):1217–25.